Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives

Published:2017-03-16 Issue:14 Volume:123 Page:2634-2641
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Wan Xiao Min¹²,Peng Liu Bao¹,Ma Jin An³,Li Yuan Jian²

Affiliation:

1. Department of Pharmacy, The Second Xiangya Hospital; Central South University; Changsha Hunan 410011 China

2. Department of Pharmacology, School of Pharmaceutical Sciences; Central South University; Changsha Hunan 410078 China

3. Department of Oncology, The Second Xiangya Hospital; Central South University; Changsha Hunan 410011 China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference40 articles.

1. Cancer statistics in China, 2015;Chen;CA Cancer J Clin.,2016

2. National Cancer Institute Cancer stat facts: kidney and renal pelvis cancer http://seer.cancer.gov/statfacts/html/kidrp.html 2017

3. Renal cancer;Capitanio;Lancet.,2016

4. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma;Remak;J Clin Oncol.,2008

5. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet.,2008

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China;Frontiers in Pharmacology;2024-07-12

3. The cost–effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma;Pharmacogenomics;2024-04-12

4. Sensitivity Analysis in Economic Evaluations of Immuno-Oncology Drugs: A Systematic Literature Review;Value in Health Regional Issues;2023-09

5. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression;Clinical Breast Cancer;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3